Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, ...
Novo will pay $200 million to gain control of the protein manufacturing factory. Elsewhere, Roivant dropped a drug program ...
The company, which raised $84 million, sees validation of its GIP-blocking approach to weight loss in Amgen's recent MariTide ...
The struggling biotech company is looking to break into the lucrative hepatitis C market with the promise of an easier ...
The AIntibody Challenge seeks to rigorously test AI-driven antibody design and in silico predictions against experimentally validated datasets. Focusing on antibodies targeting the RBD ...
The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that ...
At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...
While early and from a small trial, the findings suggest Janux’s method of “masking” T cell engagers could lead to ...
The company reached a deal to divest its third biosimilar this year, selling a copycat version of Amgen’s Neulasta for up to ...
Using tumor-treating fields alongside chemotherapy improved patient survival, Novocure said. Elsewhere, Cytokinetics got a ...
Executives at Applied Therapeutics told analysts they were surprised by the agency’s refusal to approve the company’s ...
The biotechnology company, which sees itself as "pretty conservative," recently put out an ambitious long-term revenue ...